Infectious Disease Models and Innovative Therapies
Impact in
- Virology top 5%
- HIV Research and Treatment
-
- Cancer Immunotherapy and Biomarkers
Papers in
- Virology 107
- HIV Research and Treatment 102
-
- SARS-CoV-2 and COVID-19 Research 40
- Top scholars
- Olivier LambotteRoger Le GrandXavier MarietteJean‐Marie MichotStéphane ChampiatBenoı̂t FavierAurélien MarabelleManuel Ramos‐Casals
- Journals
- Frontiers in Immunology (35 papers)Nature Communications (20 papers)PLoS ONE (13 papers)Journal of Virology (12 papers)European Journal of Cancer (12 papers)
- Partner nations
- FranceUnited StatesUnited Kingdom
In The Last Decade
Infectious Disease Models and Innovative Therapies
446 papers receiving 14.4k citations
Peers
Comparison fields: 5 of 145
- Virology 1.6k
- Oncology 4.2k
- Infectious Diseases 1.6k
- Immunology 1.4k
- Genetics 362
Countries citing scholars working at Infectious Disease Models and Innovative Therapies
This map shows the geographic impact of research produced by authors working at Infectious Disease Models and Innovative Therapies. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Infectious Disease Models and Innovative Therapies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Infectious Disease Models and Innovative Therapies more than expected).
Fields of papers published by authors at Infectious Disease Models and Innovative Therapies
This network shows the impact of papers affiliated with Infectious Disease Models and Innovative Therapies at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Infectious Disease Models and Innovative Therapies at the time of their publication.
About Infectious Disease Models and Innovative Therapies
In recent decades, authors affiliated with Infectious Disease Models and Innovative Therapies have published 482 papers, which have received a total of 14.5k indexed citations . Scholars at this organization have produced 107 papers in Virology, 62 papers in Infectious Diseases, 51 papers in Immunology, 25 papers in Ophthalmology and 70 papers in Public Health, Environmental and Occupational Health on the topics of HIV Research and Treatment (102 papers), SARS-CoV-2 and COVID-19 Research (40 papers), Cancer Immunotherapy and Biomarkers (29 papers), Malaria Research and Control (23 papers), Ocular Surface and Contact Lens (22 papers), Mosquito-borne diseases and control (15 papers), Multiple Sclerosis Research Studies (15 papers) and Ocular Infections and Treatments (14 papers). Their work is cited by papers focused on Virology (1.6k citations), Oncology (4.2k citations), Infectious Diseases (1.6k citations), Immunology (1.4k citations) and Genetics (362 citations). Authors at Infectious Disease Models and Innovative Therapies collaborate with scholars in France, United States and United Kingdom and have published in prestigious journals including Frontiers in Immunology, Nature Communications, PLoS ONE, Journal of Virology and European Journal of Cancer. Some of Infectious Disease Models and Innovative Therapies's most productive authors include Olivier Lambotte, Roger Le Grand, Xavier Mariette, Jean‐Marie Michot, Stéphane Champiat, Benoı̂t Favier, Aurélien Marabelle, Manuel Ramos‐Casals, Maria Eugenia Suarez-Almazor and Anne-Laure Voisin.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.